Introduction {#s1}
============

Mutations in the *EIF2B1*-*5* genes (OMIM 606686, 606454, 606273, 606687, 603945) encoding the subunits of the ubiquitously expressed eukaryotic initiation factor 2B (eIF2B) have been reported in a group of clinically heterogeneous leukodystrophies termed eIF2B-related disorders [@pone.0008318-Schiffmann1], [@pone.0008318-vanderKnaap1], [@pone.0008318-Leegwater1], [@pone.0008318-vanderKnaap2]. Disease severity is correlated with age at disease onset, with stress onset trigger or aggravating factors [@pone.0008318-Fogli1], [@pone.0008318-Labauge1]. A large clinical spectrum is observed and several distinct forms have been proposed: i) the classical childhood ataxia with central hypomyelination/vanishing white matter disease (CACH/VWM, OMIM 603896), with progressive neurological deterioration between age 2-5 years [@pone.0008318-Schiffmann1], [@pone.0008318-Leegwater1], ii) the infantile severe forms with disease onset \<2 years and rapid fatal evolution [@pone.0008318-Fogli2], iii) the most severe antenatal forms responsible for fetal death [@pone.0008318-vanderKnaap3], and iv) the milder forms with disease onset \>5 years and restricted to slow cognitive impairment [@pone.0008318-Labauge1], [@pone.0008318-Fogli3].

The typical MRI pattern shows a diffuse CSF-like aspect of the cerebral white matter of the cerebral hemispheres and this pattern recognition permits the selection of patients eligible for the *EIF2B1-5* genes sequencing [@pone.0008318-Schiffmann2]. But MRI can lack particularly in the adult forms whereas an increasing number of patients with clinical and MRI criteria for CACH/VWM disease but without *EIF2B1-5* genes mutations (CACH/VWM-like) are found, underlining the necessity to have biochemical markers to help in the diagnosis process and in the selection of patients eligible for *EIF2B1-5* direct sequencing.

Two biochemical markers have been recently proposed as potential tools for the screening of eIF2B-related disorders: the decrease of asialotransferrin/total transferrin in CSF [@pone.0008318-Vanderver1], [@pone.0008318-Vanderver2], and the decrease of the eIF2B GEF activity measured in Epstein-Barr Virus (EBV)-transformed lymphocytes or lymphoblasts (LLB) [@pone.0008318-Fogli4]. In fact, eIF2B is a key regulator of the protein synthesis particularly under cellular stresses through its nucleotide guanine exchange (GEF) activity: it converts the initiation factor 2 (eIF2) from an inactive GDP-bound form to an active eIF2-GTP complex [@pone.0008318-Gomez1]. Measurement of eIF2B GEF activity in patients\' LLB has been proposed as a potential diagnostic tool relating to a previous work showing decrease of this GEF activity in LLB from 30 affected eIF2B-mutated patients in comparison to controls. In order to further evaluate the specificity and sensitivity of eIF2B GEF activity in patients\' LLB regarding the diagnosis of eIF2B-related disorders, we extended this initial cohort of 30 to 63 mutated patients and compared the results not only to healthy non mutated subjects but also to patients with defined leukodystrophies or CACH/VWM-like diseases.

Methods {#s2}
=======

Objectives {#s2a}
----------

Our hypothesis is that eIF2B GEF activity measurement in LLB is a specific and sensitive marker that would be powerful to select patients eligible for the *EIF2B1-5* genes sequencing and then to help in the molecular diagnosis of eIF2B-related disorders. Our objective is then to extend our initial cohort of 30 [@pone.0008318-Fogli4] to 63 eIF2B-mutated patients and to compare the results to healthy subjects but also to CACH/VWM-like patients, in order to evaluate the specificity and sensitivity of eIF2B GEF activity in patients\' LLB regarding the diagnosis of eIF2B-related disorders.

Participants {#s2b}
------------

The GEF activity was measured in LLB from 63 eIF2B-mutated patients (including 30 patients already reported [@pone.0008318-Fogli4] and 13 patients never reported todate, ([Table 1](#pone-0008318-t001){ref-type="table"}), 18 clinically healthy subjects (controls) and 38 patients with leukodystrophies of other causes, termed eIF2B-unrelated leukodystrophic group ([Table 2](#pone-0008318-t002){ref-type="table"}). This last group included:

-   19 leukodystrophic patients with an identified genetic defect and termed OL (other leukodystrophy)-patients: 9 *GFAP-*mutated patients (with Alexander disease, OMIM 203450), 5 *MLC1*-mutated patients (with megalencephalic leukoencephalopathy with cysts, OMIM 604004) and 5 *PLP1*-mutated patients (with Pelizaeus-Merzbacher disease, PMD, OMIM 312080);

-   19 patients with the presence of clinical and/or MRI features observed in eIF2B-related disorders but screened negative for mutations in the coding regions of the five *EIF2B1-5* genes genes, and termed CACH-VWM-like patients.

10.1371/journal.pone.0008318.t001

###### Clinical data and eIF2B GEF activity measured in lymphoblasts from the 63 eIF2B-mutated patients.

![](pone.0008318.t001){#pone-0008318-t001-1}

  Patient[a](#nt101){ref-type="table-fn"}    Age at disease onset (y)   Disease evolution (y)   Score of disability[b](#nt102){ref-type="table-fn"}   Mutated gene   Amino-acid change[c](#nt103){ref-type="table-fn"}   eIF2B GEF activity (%)[d](#nt104){ref-type="table-fn"}   \% AT[e](#nt105){ref-type="table-fn"}
  ----------------------------------------- -------------------------- ----------------------- ----------------------------------------------------- -------------- --------------------------------------------------- -------------------------------------------------------- ---------------------------------------
  [1187-1]{.ul}                                         57                       11                                      3                              *EIF2B3*                   p.Ser14Phe/p.Ala87Val                                    [111.6±3.6]{.ul}                                       NA
  [1074-1]{.ul}                                         8                        NA                                     NA                              *EIF2B5*                  p.Arg113His/p.Arg113His                                   [108±11.2]{.ul}                                        NA
  971-1                                                 5                        11                                      1                              *EIF2B3*                       p.Glu136Pro/?                                        [105.5±6.8]{.ul}                                       NA
  [1135-1]{.ul}                                         5                        1.1                                     2                              *EIF2B5*                  p.Arg113His/p.Arg315Cys                                    [99±7.4]{.ul}                                         NA
  \*432-1                                               3                        8.2                                     5                              *EIF2B5*                   p.Arg113His/p.Trp628X                                    [90.4±1.8]{.ul}                                       2.11
  356-1                                                 3                        16                                      5                              *EIF2B4*                  p.Pro243Leu/p.Pro243Leu                                   [80.4±2.8]{.ul}                                        NA
  736-1                                                 8                         4                                      1                              *EIF2B4*                  p.Arg374Cys/p.Arg374Cys                                         80±0                                             NA
  630-1                                                4.5                      10.5                                     4                              *EIF2B5*                  p.Arg113His/p.Arg113His                                       77.5±2.5                                          5.50
  \*370-2                                              4.5                        5                                      3                              *EIF2B5*                  p.Arg113His/p.Arg195His                                        77±2.5                                            NA
  [1304-1]{.ul}                                         18                       32                                      2                              *EIF2B5*                  p.Arg113His/p.Arg113His                                   [76.1±4.3]{.ul}                                        NA
  1008-1                                                18                        7                                      5                              *EIF2B5*                  p.Arg113His/p.Arg113His                                   [76.1±2.6]{.ul}                                        NA
  954-1                                                3.5                        4                                      4                              *EIF2B5*                  p.Arg113His/p.Arg269Leu                                   [75.9±1.6]{.ul}                                       7.77
  \*76-1                                                17                        8                                      1                              *EIF2B2*                  p.Glu213Gly/p.Lys273Arg                                       75.5±10                                            NA
  299-1                                                 11                       17                                      4                              *EIF2B5*                  p.Arg113His/p.Arg113His                                   [75.2±5.5]{.ul}                                        NA
  338-1                                                 10                       16                                      5                              *EIF2B5*                  p.Arg113His/p.Arg113His                                       75.2±1.5                                           NA
  [1407-1]{.ul}                                         24                        2                                      1                              *EIF2B5*                  p.Arg113His/p.Arg222Trp                                   [74.9±0.8]{.ul}                                        NA
  \*370-1                                              3.5                        7                                      3                              *EIF2B5*                  p.Arg113His/p.Arg195His                                        71.5±9                                            NA
  73-1                                                  4                        11                                      3                              *EIF2B5*                  p.Arg113His/p.Arg113His                                    [70.8±7]{.ul}                                         NA
  904-1                                                 2                        1.5                                     1                              *EIF2B5*                p.Arg113His/p.Gly481fs493X                                       70±1.2                                           4.52
  1014-1                                                16                       0.5                                     0                              *EIF2B5*                  p.Arg113His/p.Arg195Cys                                         68±4                                             NA
  \*470-2                                               2                         4                                      1                              *EIF2B5*                  p.Glu81Lys/p.Arg113His                                    [67.9±1.8]{.ul}                                        NA
  [1240-1]{.ul}                                         17                        4                                      0                              *EIF2B3*                   p.Ala202Thr/p.Arg438X                                     [67.7±2]{.ul}                                         NA
  [1627-1]{.ul}                                         7                        24                                      3                              *EIF2B5*                  p.Pro87Leu/p.Arg113His                                    [67.1±1.8]{.ul}                                        NA
  \*76-2                                                7                        11                                      3                              *EIF2B2*                  p.Glu213Gly/p.Kys273Arg                                        67±5.1                                            NA
  807-1                                                 6                        4.5                                     3                              *EIF2B5*                  p.Arg113His/p.Arg113His                                    [67±4.3]{.ul}                                         NA
  435-1                                                 3                        5.5                                     3                              *EIF2B5*                   p.Arg113His/p.Arg422X                                          67±3                                             NA
  [1467-1]{.ul}                                         25                       19                                      1                              *EIF2B5*                  p.Tyr483Cys/p.Arg195His                                   [66.3±0.6]{.ul}                                        NA
  [1232-1]{.ul}                                         28                        3                                      1                              *EIF2B5*                      g.IVS8+59A/G/?                                        [64.3±7.8]{.ul}                                        NA
  \*648-2                                               7                         3                                      1                              *EIF2B2*                  p.Glu213Gly/p.Glu213Gly                                         64±4                                            4.11
  [1108-1]{.ul}                                        3.5                       1.5                                     4                              *EIF2B5*                p.Arg113His/c.\[+2081delG\]                                 [63.6±2.3]{.ul}                                        NA
  [1115-1]{.ul}                                         2                         6                                      2                              *EIF2B5*                  p.Pro427Leu/p.Pro427Leu                                   [63.4±8.2]{.ul}                                        NA
  [1441-1]{.ul}                                        2.8                       3.2                                     4                              *EIF2B5*                  p.Leu106Phe/p.Arg113His                                    [63.2±2]{.ul}                                         NA
  997-1                                                 7                         4                                      1                              *EIF2B5*                  p.Arg113His/p.Arg113His                                       61.3±0.3                                           NA
  \*823-1                                               4                         2                                      4                              *EIF2B3*                  p.His341Gln/p.His341Gln                                         61±6                                             NA
  \*576-2                                               7                         5                                      0                              *EIF2B5*                  p.Tyr343Cys/p.Ile385Val                                        61±0.2                                            NA
  1012-1                                                14                       10                                      5                              *EIF2B2*                  p.Glu213Gly/p.Glu213Gly                                         60±2                                             NA
  663-1                                                3.5                       1.5                                     1                              *EIF2B5*                  p.Arg113His/p.Arg113His                                   [59.9±3.8]{.ul}                                        NA
  1004-1                                                2                         1                                      1                              *EIF2B2*                  p.Glu213Gly/p.Glu213Gly                                   [59.9±0.8]{.ul}                                        NA
  \*375-2                                              2.5                        3                                      5                              *EIF2B5*                  p.Arg113His/p.Glu650Leu                                   [59.4±0.7]{.ul}                                        NA
  \*648-1                                               7                        14                                      4                              *EIF2B2*                  p.Glu213Gly/p.Glu213Gly                                         59±1                                             NA
  442-1                                                2.5                       NA                                     NA                              *EIF2B5*                  p.Glu81Lys/p.Arg113His                                        58.8±0.3                                           NA
  308-1                                                 5                         8                                      4                              *EIF2B5*                  p.Arg113His/p.Arg113His                                   [57.1±6.1]{.ul}                                        NA
  \*576-1                                               8                        11                                      1                              *EIF2B5*                  p.Val73Gly/p.Arg113His                                          56±4                                             NA
  359-1                                                 6                        1.5                                     5                              *EIF2B4*                  p.Pro243Leu/p.Pro243Leu                                         54±6                                             NA
  522-1                                                3.5                       3.5                                     3                              *EIF2B5*                  p.Ala16Asp/p.Arg113His                                          54±6                                            4.80
  \*432-2                                               2                        8.2                                     5                              *EIF2B5*                   p.Arg113His/W628stop                                     [53.9±0.9]{.ul}                                        NA
  \*570-2                                              1.5                       6.5                                     4                              *EIF2B4*                  p.Arg209Gln/p.Arg209Gln                                         52±3                                             NA
  \*470-1                                               3                         4                                      1                              *EIF2B5*                  p.Glu81Lys/p.Arg113His                                    [51.5±4.5]{.ul}                                        NA
  984-1                                                 5                         4                                      2                              *EIF2B2*                  p.Glu213Gly/p.Glu213Gly                                       51.5±0.5                                           NA
  \*571-2                                              1.2                        9                                      5                              *EIF2B5*                  p.Phe56Val/p.Arg315His                                          50±5                                             NA
  928-1                                                 3                         5                                      1                               EIF2B5                   p.Arg113His/p.Arg113His                                         49±3                                             NA
  995-1                                                 1                         2                                      4                              *EIF2B5*                  p.Arg113His/p.Leu425Arg                                         48±2                                             NA
  \*590-2                                               1                         4                                      5                              *EIF2B5*                  p.Tyr343Cys/p.Ile385Val                                   [45.8±2.2]{.ul}                                       4.36
  949-1                                                 4                         9                                      4                              *EIF2B4*                  p.Pro243Leu/p.Pro243Leu                                   [45.6±1.8]{.ul}                                        NA
  \*590-1                                               3                         4                                      3                              *EIF2B5*                  p.Tyr343Cys/p.Ile385Val                                   [44.9±4.3]{.ul}                                        NA
  357-1                                                 2                         2                                      5                              *EIF2B5*                  p.Arg136Cys/p.Arg339Trp                                       44.5±4.5                                           NA
  291-1                                                1.5                       6.5                                     4                              *EIF2B5*                  p.Arg113His/p.Arg113His                                        41.5±6                                            NA
  \*571-1                                              0.8                        9                                      5                              *EIF2B5*                  p.Phe56Val/p.Arg315His                                          40±3                                             NA
  569-1                                                3.5                      19.5                                     4                               EIF2B5                  p.Arg113His/p.256_281del                                         40±2                                             NA
  [1388-1]{.ul}                                         22                       17                                      1                              *EIF2B5*                   p.His214Arg/p.Arg269X                                      [39±7]{.ul}                                          NA
  942-2                                                 6                         7                                      1                              *EIF2B4*                 p.Cys465Arg/p.Tyr489TThr                                    [34.5±1]{.ul}                                         NA
  137-1                                                 5                        7.5                                     1                              *EIF2B2*                  p.Glu213Gly/p.Glu213Gly                                   [33.9±3.2]{.ul}                                        NA
  1036-1                                               0.8                       0.5                                     5                              *EIF2B5*                  p.Pro323Ser/p.Pro427Leu                                        30±7.5                                            NA

\*  =  Familial form: two affected children in the same family; underlined: new patients whose genotype has not been reported in our previous studies [@pone.0008318-Fogli1], [@pone.0008318-Fogli4].

score of disability as previously described [@pone.0008318-Fogli1]: 0: no neurologic signs, 1: stiff gait, 2: walk with help, 3: wheelchair-bound, 4: help for daily living, 5: death.

Amino-acid numbers refer to the eIF2B peptide corresponding sequence.?  =  mutation not yet identified.

Expressed as % control value ± standard deviation (assays performed in triplicate); underlined: new eIF2B GEF activity measured and not reported in [@pone.0008318-Fogli4].

Asialotransferrin ratio (AT) in % already described [@pone.0008318-Vanderver1], [@pone.0008318-Vanderver2]. NA: Not available.

10.1371/journal.pone.0008318.t002

###### eIF2B GEF activity measured in lymphoblasts from the 38 leukodystrophic patients (19 OL and 19 CACH/VWM-like) and the 18 controls.

![](pone.0008318.t002){#pone-0008318-t002-2}

  Patient    Disease[a](#nt106){ref-type="table-fn"}   Mutated gene   Mutation[b](#nt107){ref-type="table-fn"}   eIF2B GEF activity (%)[c](#nt108){ref-type="table-fn"}
  --------- ----------------------------------------- -------------- ------------------------------------------ --------------------------------------------------------
  81                           PMD                        *PLP1*                    duplication                                        108.6±10.4
  1437                         AD                         *GFAP*                    p.Asp114Glu                                        103.8±6.6
  940                          MLC                        *MLC1*                      p.Leufs                                          109.6±0.4
  002                          PMD                        *PLP1*                    duplication                                         98.4±1.3
  672                          AD                         *GFAP*                     p.Asn77Tyr                                         133.6±9
  958                          AD                         *GFAP*                    p.Arg407Met                                        113.2±5.1
  150                          PMD                        *PLP1*                    duplication                                        103.4±4.5
  42                           PMD                        *PLP1*                    duplication                                         86.2±4.4
  726                          AD                         *GFAP*                    p.Arg239Cys                                        119.8±1.6
  989                          AD                         *GFAP*                     p.Met74Lys                                        101.5±8.4
  256                          MLC                        *MLC1*                         NA                                            102.6±4.3
  737                          AD                         *GFAP*                     p.Arg88Cys                                         101±14.8
  1047                         MLC                        *MLC1*                   p.Ser289Tyr/?                                        98.7±13
  750-1                        AD                         *GFAP*                     p.Arg79His                                        105.6±1.8
  750-2                        AD                         *GFAP*                     p.Arg79His                                         79.9±3.9
  613                          MLC                        *MLC1*                         NA                                            101.8±2.5
  968                          PMD                        *PLP1*                    duplication                                        105.9±6.3
  1207                         MLC                        *MLC1*                     p.Cys46fs                                         107.7±5.3
  758                          AD                         *GFAP*                     p.Arg88Cys                                         96.4±4.4
  1011-1                     CACH-L                         \-                           \-                                            104.43±6.5
  1242-1                     CACH-L                         \-                           \-                                            105.29±8.8
  1469-1                     CACH-L                         \-                           \-                                            103.30±1.7
  1479-1                     CACH-L                         \-                           \-                                            99.75±2.2
  1082-1                     CACH-L                         \-                           \-                                             89.5±8.8
  1196-1                     CACH-L                         \-                           \-                                            110.4±3.3
  1290-2                     CACH-L                         \-                           \-                                            105.9±2.7
  1211-1                     CACH-L                         \-                           \-                                             87.4±5.1
  1200-1                     CACH-L                         \-                           \-                                             108.5±2
  798-1                      CACH-L                         \-                           \-                                            119.0±2.3
  1253-1                     CACH-L                         \-                           \-                                            107.6±6.6
  1206-1                     CACH-L                         \-                           \-                                            94.67±8.2
  K80                        CACH-L                         \-                           \-                                            89.27±2.6
  K128                       CACH-L                         \-                           \-                                            84.76±1.2
  K112                       CACH-L                         \-                           \-                                            100.41±2.5
  1313-1                     CACH-L                         \-                           \-                                            82.02±1.2
  1283-1                     CACH-L                         \-                           \-                                            101.40±6.8
  1454-1                     CACH-L                         \-                           \-                                             111±16.6
  331-1                      CACH-L                         \-                           \-                                             88.3±9.5
  N1                            C                           \-                           \-                                               100
  N2                            C                           \-                           \-                                                99
  N3                            C                           \-                           \-                                               101
  N4                            C                           \-                           \-                                               100
  N5                            C                           \-                           \-                                               102
  N6                            C                           \-                           \-                                               100
  N7                            C                           \-                           \-                                                98
  N8                            C                           \-                           \-                                               100
  N9                            C                           \-                           \-                                              94.3±7
  N10                           C                           \-                           \-                                             100±0.3
  N11                           C                           \-                           \-                                             95.3±7.5
  N12                           C                           \-                           \-                                             88.5±1.5
  N13                           C                           \-                           \-                                             97.5±2.5
  N14                           C                           \-                           \-                                              99.5±7
  N15                           C                           \-                           \-                                             99.3±6.1
  N16                           C                           \-                           \-                                             93.5±0.5
  N17                           C                           \-                           \-                                             96.5±0.5
  N18                           C                           \-                           \-                                              102±2

OL: PMD: Pelizaeus-Merzbacher disease, AD: Alexander disease, MLC: Megalencephalic Leukoencephalopathy with Cysts; and CACH/VWM-like: CACH-L.

?: second mutation not yet identified; NA: not available.

Expressed as % control value ± standard deviation (assays performed in triplicate); underlined: new eIF2B GEF activity measured and not reported in [@pone.0008318-Fogli4].

Measurement of eIF2B GEF Activity in Transformed Lymphocytes {#s2c}
------------------------------------------------------------

The direct GEF activity of the eIF2B complex was measured in triplicate in protein extracts from patients\'EBV-transformed lymphocytes (LLB) as already described [@pone.0008318-Fogli4], [@pone.0008318-Neitzel1].

Ethics {#s2d}
------

An Institutional Review Board of the participating centers (Comité de Protection des Personnes Sud-Est VI, 2009-A00188-49) approved the use of human subjects for this study. A written informed consent was obtained from all patients.

Statistical Methods {#s2e}
-------------------

The eIF2B GEF activity was considered as a continuous variable and results are displayed as mean ± SEM (standard error of the mean). Since the normality of eIF2B GEF (assessed by a Kolmogorov-Smirnov test) was not rejected, a one-way analysis of variance (ANOVA 1) was performed to assess the links between GEF activity and the patients\'groups. On condition of a significant F-test for the ANOVA 1, a post-hoc multiple comparisons procedure was performed controlling for a 5% family-wise type I error using the Tukey honestly significant difference (THSD) test. A Spearman correlation coefficient (r) was calculated between GEF activity and age at disease onset (correleted to disease severity [@pone.0008318-Fogli1]). The Receiver Operating Characteristic, or ROC curve analysis (graphical plot of the sensitivity *versus* (1-specificity) for a binary classifier system as its discrimination threshold is varied), was performed on MedCalc® (v10.4, Mariakerke, Belgium) to determine the optimal threshold of GEF activity which best discriminates between eIF2B-mutated (n = 63) and eIF2B-unrelated leukodystrophic patients (n = 38), aiming a 100% specificity and the best associated sensitivity. The area under the ROC curve (AUC) was also estimated (with its 95% confidence limits) and tested towards 0.5. All remaining statistical analyses were performed on SAS® (v9.1, Cary, USA) with a type I error set at 5%.

Results {#s3}
=======

eIF2B GEF Activity in 63 eIF2B-Mutated Patients in Comparison to the Other Groups {#s3a}
---------------------------------------------------------------------------------

The eIF2B GEF activity was measured in LLB of 63 affected patients exhibiting various eIF2B mutations, age of onset and disease severity ([Table 1](#pone-0008318-t001){ref-type="table"}). Despite the wide range of GEF activity in eIF2B-mutated cells (63.2±17.1%, range: 30--111.6%) ([Figure 1A](#pone-0008318-g001){ref-type="fig"}), multiple comparisons demonstrated a significant difference between the group of eIF2B-mutated patients (n = 63) and the three other groups of patients \[OL-patients (104.1±11.4%, range: 80--133.6%, n = 19), CACH/VWM-like (99.6±10.3%, range: 82--119%, n = 19) and controls (98±3.3%, range: 88.5--102%, n = 18)\] (F(3,115)  = 71.1, p\<0.001) ([Tables 1](#pone-0008318-t001){ref-type="table"} and [2](#pone-0008318-t002){ref-type="table"}, [Figures 1A](#pone-0008318-g001){ref-type="fig"} and [2](#pone-0008318-g002){ref-type="fig"}). The OL, CACH/VWM-like and controls groups had similar GEF activity (THSD test). The THSD test further detailed that only the eIF2B-mutated group had significantly lower GEF activity compared with each of the three other groups (OL, CACH/VWM-like and controls).

![Distribution of patients per classes of eIF2B GEF activity.\
**A**. Distribution of the patients\'groups per classes of eIF2B GEF activity in %. The patients\' groups are healthy controls, eIF2B-mutated, others leukodystrophies (OL) and CACH-VMW-like. **B**. Distribution of the 63 eIF2B-mutated patients per classes of eIF2B GEF activity. The mutated patients have been classified into three clinical groups depending of their clinical severity, according to previous studies [@pone.0008318-Fogli1]. Form 1: disease onse before 2 years, form 2: disease onset berween 2 and 5 years, form 3: disease onset \>5 years.](pone.0008318.g001){#pone-0008318-g001}

![Decreased eIF2B GEF activity in eIF2B-mutated patients\' lymphoblasts (LLB).\
The eIF2B GEF activity was measured in LLB from 63 eIF2B-mutated patients in comparison to 8 healthy controls, 19 patients carrying other leukodystrophies (OL: 9 patients with Alexander disease, AD, 5 patients with Pelizaeus-Merzbacher disease, PMD, and 5 patients with Megalencephalic leukoencephalopathy with cysts, MLC), and 19 CACH/VWM-like patients without eIF2B mutations. Experiments were carried out in triplicate. Data are presented as percentage of exchange activity of control LLB. The statistical multiple comparisons analysis between all the seven groups showed significant differences (\*) only for the eIF2B-mutated group (p\<0.001).](pone.0008318.g002){#pone-0008318-g002}

Pooling CACH/VWM-like patients and OL-patients (group of eIF2B-unrelated leukodystrophic patients, n = 38), the aforementioned comparison of GEF activity led still to a significant result (F(2,116)  = 106.1, p\<0.0001) and the THSD test showed again the same significantly lower GEF activity in the eIF2B-mutated group as compared with each of the two other groups (eIF2B-unrelated leukodystrophic and controls). Then difference in GEF activity remained statistically significant between eIF2B-mutated patients and the other groups tested.

Correlation between Age at Disease Onset and GEF Activity {#s3b}
---------------------------------------------------------

A weak correlation was found between GEF activity measured in the eIF2B-mutated LLB and age at disease onset (r = 0.4309, p = 0.0004). Two patients 356--1 and 432--1 ([Table 1](#pone-0008318-t001){ref-type="table"}) exhibited high GEF activities (respectively 80.4±2.8% and 90.4±1.8%) despite a classical clinical form (disease onset at 3 years followed by severe disability within 3 years and death occurring after 16 years in one patient). On the other hand, patient 1388--1 affected with an adult onset, slowly progressive form (only stiff gait after 17 years of disease progression), exhibited a low GEF activity (39±7%) ([Table 1](#pone-0008318-t001){ref-type="table"}). However, the eight patients with onset ≤2 years (disease severity form 1) always had eIF2B GEF activity \<55% (45.1±7.8%, mean age at disease onset: 1.2 year) ([Table 1B](#pone-0008318-t001){ref-type="table"}). The correlation coefficient is higher in this group of eight patients (r = 0.68, p = 0.06) compared to the 30 patients carrying the clinical severity form 2 with onset between 2 and 5 years (r = 0.11, p = 0.52), and to the 25 patients carrying the severity form 3 with onset \>5 years (r = 0.45, p = 0.0218) ([Table 1B](#pone-0008318-t001){ref-type="table"}).

ROC Curve Analysis of eIF2B GEF Activity in the Leukodystrophic Groups {#s3c}
----------------------------------------------------------------------

Three out of the 63 eIF2B-mutated patients (4.8%) had GEF activity \>100%. They expressed a mild juvenile/adult form of the disease with onset ≥5 years of age ([Table 1](#pone-0008318-t001){ref-type="table"}). The ROC curve analysis of eIF2B GEF activity performed towards differential diagnosis between eIF2B-related (n = 63) and eIF2B-unrelated (n = 38) leukodystrophy patients lead to a pathognomonic threshold "≤77.5% of GEF activity", achieving 100% specificity (95% CL = 90.7--100%) and 88.9% sensitivity (95% CL = 78.4--95.4%), with an almost perfect discrimination (AUC = 0.96±0.024, p\<0.0001) ([Figure 3](#pone-0008318-g003){ref-type="fig"}). Only 7/63 (11.1%) eIF2B-mutated patients had GEF activities \>77.5%. These patients presented with classic to milder clinical forms with onset ranging from 3 to 57 years, slow disease progression, and carrying mutations in different *EIF2B1-5* genes ([Table 1](#pone-0008318-t001){ref-type="table"}). This group illustrates that the high level of GEF activity found is not linked to the type of mutated gene nor to a specific degree of clinical severity. However, none of these patients had a disease onset \<3 years.

![ROC (Receiver Operating Characteristic) curve of eIF2B GEF activity regarding the diagnosis of eIF2B-related disorders.\
The ROC curve analysis was performed to determine the optimal threshold of GEF activity which best discriminates between eIF2B-mutated (n = 63) and eIF2B-unrelated leukodystrophic patients (n = 38). The ≤77.5% threshold achieves 100% specificity (95% CL = 90.7--100%) and 88.9% sensitivity (95% CL = 78.4--95.4%). The area under the ROC curve (AUC)  = 0.955; standard error  = 0.0244; 95% confidence interval: 0.894 to 0.986; test for the: AUC  = 0.5, p = 0.0001.](pone.0008318.g003){#pone-0008318-g003}

Discussion {#s4}
==========

Analysis of this extended cohort showed that eIF2B GEF activity measured in patients\' LLB distinguishes eIF2B-mutated patients from those with eIF2B-unrelated leukodystrophies with 100% positive predictive value (PPV) and 89% negative predictive value at ≤77.5% threshold. At this threshold, the assay systematically excludes patients without eIF2B mutations. Therefore, it represents an interesting screening tool to select patients for a direct sequencing of the *EIF2B1-5* genes. For leukodystrophic patients with \>77.5% GEF activity, the probability to find eIF2B mutations is 15% (7/45) and increases to 26.9% (7/26) if patients have clinical and/or MRI features typical to eIF2B-related disorder. Therefore, *EIF2B1-5* sequencing is still indicated for patients who are clinically suspected of eIF2B-related disorder with GEF activity \>77.5%, particularly in milder forms.

The wider range of disease onset reported in this cohort in comparison to previous work [@pone.0008318-Fogli4] may explain the weaker correlation found between age at disease onset and GEF activity. Such correlation is better in severe forms with GEF activity \<55% for patients with onset \<2 years ([Figure 1B](#pone-0008318-g001){ref-type="fig"}). Discrepancies in the GEF activity values were found among patients of the same group of disease onset or with the same mutations such as siblings 432--1 and 432--2 (GEF activities at respectively 90% and 53.9%), confirming that GEF activity in LLB is modulated by factors other than eIF2B mutations.

Determination of the asialotransferrin/total transferrin ratio in CSF is also a reliable marker to distinct eIF2B-mutated from non-mutated patients with 100% sensitivity and 94% specificity associated to 8%-ratio threshold [@pone.0008318-Vanderver2]. This marker has been determined in parallel for five of our 63 eIF2B-mutated patients and a decreased ratio has been found in CSF ([Table 1](#pone-0008318-t001){ref-type="table"}) in all five, including patient 432--1 with a surprisingly normal eIF2B GEF activity (90.4±1.8%) compared to his sibling. This suggests that these two biomarkers, if available for the same patient, may be complementary in order to assess with 100% sensitivity, specificity and PPV.

Limitations {#s4a}
-----------

Limitations of this study are:

-   the relatively small number of patients overall, as eIF2B-related disorders are rare disorders;

-   the age of disease onset, that may be imprecise for some patients, since it is determined retrospectively.
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